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The middle ear mucosa is described as a non-specialized site where drug substances diffuse passively. However, precise 
pharmacokinetic studies on antibiotic penetration into middle ear effusion (MEE) are difficult to conduct in  humans 
because of ethical and methodological problems: (1) studies must involve the population in which acute otitis 
media (AOM) is most frequent (i.e. in children from 3 months to  3 years of age); (2) studies are commonly performed 
during surgery for chronic otitis media with effusion, whereas drug penetration into MEE is higher during AOM; 
(3) kinetics are deduced from data per individual obtained in groups with marked interindividual variations. Furthermore, 
the results of different studies are difficult to compare because of differences in protocols, antibiotic assay methods and 
interpretation. Clinical studies have nonetheless shown the poorly predictive nature of serum concentrations, given the 
large differences in drug delivery to the MEE among antibiotic classes, among members of the same class, and among 
individuals receiving a given antibiotic. Experimental studies can help to narrow the gap between in vitro and clinical 
data, as the more precise pharmacokinetic data they yield can throw light on the link between drug/host/pathogen factors 
and bacteriologic efficacy. 
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I NTRO DU CTI 0 N 
Appropriate antibiotic concentrations at sites of in- 
fection are thought to be necessary for in vivo efficacy. 
I'harniacokinetic studies are required in  antibiotic 
evaluation to coinplete in vitro data [l]. The increasing 
emergence of antibiotic-resistant pathogens in otitis 
media (e.g. Stveptoroccus p z ~ ~ ~ ~ w o n i m )  has made it 
necessary to reassess existing agents. However, clinical 
pharmacokinetic studies run into methodological 
problems specific to otitis media. In this review, we 
critically analyze pharniacokinetic studies of commonly 
used antimicrobial agents in the human middle ear, and 
their contribution to predicting clinical efficacy. The 
contribution of animal phariiiacokinetic studies is also 
reviewed. 
ANTIBIOTIC DELIVERY TO THE MIDDLE EAR 
The amount of antibiotic recovered in a tissue depends 
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on the chemicophysical and biochemical properties of 
the compound (size, lipid solubility, protein binding, 
cellular accumulation), and on the nature and inflan- 
niatory status of the tissue. Many drugs are reversibly 
bound to biological molecules (most commonly pro- 
teins such as albumin) and protein binding is a major 
pharniacokinetic factor, as only free drug can access 
extracellular fluid and is active. 
The middle ear (ME) mucosa is a thin monolayer 
epithelium considered as a lion-specialized site where 
antibiotics penetrate by passive diffusion through the 
capillary meinbrane in interstitial fluid. In the healthy 
ME mucosa, lipid-soluble molecules reach lower peak 
concentrations than in serum, but the penetratioii and 
diffusion profiles appear similar [2].  
The first pathologic change during acute otitis 
media (AOM) and chronic otitis media with cff~ision 
(COME) is di1,xtation of intercellular spaces. M L I ~ O S ~ ~  
inflammatory changes arc histologically different i n  
AOM and COME, but both lead to the production of 
a retrotynipanic exudate. Antibiotic kinetics in middle 
ear effusion (MEE) conform to model with a niucosal 
surface area which is small in coInparisoii with the 
volume of exudate, resulting in slower increases and 
decreases in drug concentrations in MEE than in 
serum. 
In both AOM and COME, MEE is coniposed of 
protein, enzymes and inflaniniatory cells. However, 
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many studies comparing the penetration of antibiotics 
of various classes (penicillin, ampicillin, oxytetracycline 
and azithromycin) in AOM and COME have shown 
higher concentrations in AOM [3-61. Barr et al. [7] 
reported two pharmacokinetic studies of cefiibuten in 
AOM and one study in COME and also observed 
higher peak levels in AOM. Furthermore, the AUC 
ratio (MEE/plasma) was about 70% in AOM and only 
10% in COME, suggesting that diffusion is impaired in 
COME. Similar results were obtained in the chinchilla 
model by Canafax et al. [8 ] ,  who compared the pharma- 
cokinetics of amoxicillin in pneumococcal AOM and 
in serous otitis media (SOM) produced by obstruction 
of the eustachian tube with a silastic sponge. Concen- 
trations of amoxicillin in plasma fell rapidly (elimination 
half-life, Tv2: 0.9 h), and maximum concentrations 
(C,,,,,) of amoxicillin in MEE were 10-fold higher in 
AOM than in SOM. However, amoxicillin elimination 
was more rapid in AOM (Ti/?: 1.6 h in AOM versus 9.2 
h in SOM). In AOM the area under the time- 
concentration curves (AUCs) in plasma and MEE were 
similar, and twice those obtained in SOM. 
METHODOLOGICAL PROBLEMS IN 
PHARMACOKINETIC STUDIES OF OTITIS MEDIA 
Precise determination of antibiotic pharmacokinetics 
in human MEE is hindered by various factors: 
1. Acute otitis media mainly occurs in children under 
3 years of age. Owing to large differences with 
adults, pharmacokinetic data are needed in young 
children but there are obvious ethical and practical 
problems. 
2. Determination of drug concentrations in MEE 
during AOM is also limited by ethical considera- 
tions, and most clinical studies are performed during 
transtympanic tube insertion for COME; as already 
mentioned, drug levels are likely to be under- 
estimated relative to AOM. 
3. The impossibility of obtaining serial samples means 
that pharmacokinetics have to be deduced from data 
per individual obtained in groups of individuals. 
However, natural interindividual variations are very 
large in this setting and, despite the large groups 
involved, reliable pharmacokinetics are often im- 
possible to establish. For example, in the study by 
Shyu et al. [9] the active concentration of cefprozil 
was measured in the MEE of 89 children with 
COME after one oral administration of 15-20 
mg/kg. Sampling times ranged from 0.3 to 6 h and 
the concentrations recovered ranged from 0.02 to 
8.67 pg/mL. The wide scatter on concentration/ 
time plots ruled out computation of a reliable Ti/, 
value. In many studies mean concentrations with 
large standard deviations are the only data reported, 
the Ti/? and AUC rarely being given. 
DIFFICULTIES IN INTERPRETING ANTIBIOTIC LEVELS 
IN SERUM AND MEE IN CLINICAL STUDIES 
In addition to the inaccuracy engendered by ME patho- 
logy, protocols differ regarding antibiotic administration 
(route, dose, rate), sampling times and antibiotic assay 
methods. Such a lack of homogeneity among studies 
makes the results difficult to compare. 
Antimicrobial concentrations in serum, tissue and 
fluid are determined by means of high-performance 
liquid chromatography (HPLC) or microbiological 
assays. According to the method used, data reflect total 
and/or free drug (HPLC method) or total and/or 
microbiologically active drug (microbiological method), 
depending on the medium used to construct standard 
curves. Microbiological assays can be used to determine 
the active/total drug ratio; this differs from the free/ 
total drug ratio because of environmental factors which 
may interfere with drug activity [lo]. 
No microbiological studies comparing active and 
total concentrations of drugs in human MEE have been 
reported. However, Lildholdt et al. [ l l ]  and Krause 
et al. [12], in comparable studies with cefaclor (COME, 
dosing, sampling times), used different methods to 
determine drug concentrations. Lildholdt et al. used 
microbiological assays with a buffer standard curve and 
obtained half the active drug concentration in serum 
and six-fold lower values in MEE compared to total 
drug concentrations measured by Krause et al., using 
HPLC. 
The microbiologically active drug fraction recovered 
from MEE is probably the most valid pharmacokinetic 
parameter. As minimal inhibitory concentrations (MICs) 
are measured in protein-free media, correlations bet- 
ween MICs and total drug levels in serum or tissues 
may lead to erroneous conclusions [13]. 
The MEE/serum concentration ratio is commonly 
used as an index of drug penetration in MEE, but is 
only meaningful if the concentrations used are respec- 
tive C,,,, values and not simultaneously measured 
concentrations. Indeed, diffusion of drugs into MEE 
is delayed relative to the serum peak. Furthermore, 
proteins and inflammatory mediators which can in- 
fluence drug activity may not be the same in serum and 
MEE, and this ratio should therefore compare the 
microbiologically active drug fraction in the two 
compartments. 
C,, values in MEE are not suitable for predicting 
the bacteriologic efficacy of drugs like p-lactams whose 
efficacy is time-dependent. In this case, the time during 
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which the concentration remains above the MIC for 
the infecting organism is an important parameter which 
can only be evaluated when the TI/> is known. This is 
not true for other classes of antibiotics (quinolones, 
aniinosides and metronidazole) whose bactericidal 
effect is concentration-dependent and which have a 
postantibiotic effect. In this case the C,,,,, is a better 
predictor of drug efficacy, and long dosing intervals are 
feasible. 
OVERALL VALUE OF CLINICAL PHARMACOKINETIC 
DATA IN MEE 
Despite the large number of limiting factors, pharma- 
cokinetic studies of human ME have provided some 
valuable information. For example, it has emerged that 
the ME penetration rate differs among antibiotic classes 
and also among antibiotics in the sanie class. Therefore, 
serum levels cannot be predictive of the ME concen- 
tration. Another finding is that interindividual variations 
are very large, and this may explain clinical failures 
when antibiotic concentrations are lower than expected 
and below the MIC for the pathogen involved. 
Data have been published on the main classes of 
antibiotic used in the treatment of AOM. 
Amoxicillin has been studied in COME: high 
serum levels were reported 1 h after oral administra- 
tion, with an ME penetration rate of 40% in COME 
[12,14,15]. The MEE penetration rate is higher in 
AOM and maxinial 2 h after administration [ 161. 
Ampicillin shows poorer ME penetration than anioxi- 
cillin after oral administration of the same dose in 
COME 1141. However, in AOM the ampicillin pene- 
tration rate is approximately 50% of serum levels [3,4]. 
With the oral cephalosporins, large differences in 
penetration rates have been reported in children with 
AOM. The data shown in Table 1 also reflect differ- 
ences between clinical studies. In COME, increased 
doses of cefaclor do not increase serum or MEE levels 
[23]. There are too few data on cefuroxime-axetil to 
evaluate middle ear penetration 1241. Cefotaxime levels 
were measured in COME by Bkgut- et al. [25] after 
Table 1 Pharmacokinetics of oral cephalosporins in children with acute otitis media 
c:,, +- SI) (pg/n1L) 
(Time of sampling 
Mcthod of after List administration) 
Author Dose (mg/kg) dosage/ 
(Reference) Antibiotic x of dose\ fraction of drug Serum MEE 
I’uhakka [ 171 Cefadroxil .50/ 12 h x 4 Bioasay/ total 7.4&4.3* 5.0+-3.2* 
(4 h) (4 h) 
Barr 17) Cefaclor 1 3 3 8  h x 4 Bioassayi ? 3.6 0.96 
( 2  h) ( 2  11) 
MacLinn 11 91 Cefaclor 14 x ? O.S* 
(1) 
Kafetzis [ 181 Cefatrizine 2 0 / 1 2 h x 6  Bioassay/ ? 5.75 1.4 
(2 h) (4 h) 
Van 1)yk [20] Cefpodoxinie 4 x 1  Bioassay/ I 2.6k0.5 O.9fO.5 
(2 h) (3 14 
Barr [7] Ceftibuten 9/24 h x 2 Bioassay/ ? 6.7 4.0 
(2 h) (4 h) 
Kafetzis [18] 
I<afetzis [I81 
Barr [7] Ceftibuten 9/24 h X 3 HPLC/total 14.5 14.3 
Kusniiesz 1211 Loracarbef 7.5 x 1 Bioassay/ ? 4.2k2.0* 2.6&2.6:k 
( 2  h) (4 h) 
(1-3 h) (1-3 h) 
(1-3 h) (1-3 h)  
(3-5 11) (3-5 h) 
Kusniietz [21] Loracarbcf 15 X 1 Bioassay/ ? 9.3?4.2* 3.9k2.6* 
Harrison [22] Cefixiine 8 x 1  ? 2.5* 1.3* 
Kafetzis [18] Cefprozil 15/12 11 X 2 Bioassay/ ? .i . .5 1.98 
( 2  h) (2  h) 
C,,,,,: niaxinial concentration; MEE: middle ear effusion. 
*not CL,,,, but nican of the concentration? at the sanipling times. 
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an intramuscular dosage of 100 mg/kg four times a day. 
The mean total serum concentration 1 h after the last 
injection was 14.5 pg/niL and the MEE penetration 
rate was 30%. 
The penetration rate of macrolides into MEE also 
depends on the molecule. Erythromycin penetration 
during COME is slow, and repeated doses are necessary 
to reach steady state [26]. Mean total MEE concen- 
trations in AOM are half the serum concentrations 
[16,27]. A given dose of erythromycin estolate gives 
concentrations three to five times higher in seruni and 
ME than erythromycin ethylsuccinate [16,27,28], but 
this apparent advantage was not borne out in clinical 
studies. Clarithroniycin and its 14-OH metabolite were 
studied in COME by Sundberg et al. [29]. O n  day 3 
of treatment with 7.5 mg/kg twice a day, mean total 
MEE concentrations of clarithromycin (2.5 pg/mL) 
and its metabolite (1.3 pg/mL) were higher than corre- 
sponding serum concentrations (1.7 and 0.8 pg/mL 
respectively). A single oral dose of azithroniycin gives 
very high total drug levels in MEE, yet levels in plasma 
are near the detection limit of the assay [6]. Levels in 
AOM 24 h after initiation of therapy are twice those 
achieved in COME after a single dose of 10 nig/kg (8.6 
versus 4.0 pg/g at 24 h), and the half-life is probably 
lengthy. 
Triniethoprim and sulfonamides have only been 
studied in COME. Trimethoprim shows good penetra- 
tion into ME, with total concentrations of approxi- 
mately 75% of the serum concentration. Sulfonamides 
(sulfamethoxazole and sulfisoxazole) give very high 
total serum levels and a 20-30% penetration rate in 
COME [11,30]. 
CONTRIBUTION OF EXPERIMENTAL 
PHARMACOKINETIC STUDIES IN ME 
It  is easier to obtain reproducible data on antibiotic 
distribution in animals. Similar disease states can be 
induced in all animals with a given pathogen, and a 
large number of samples can be taken to draw reliable 
pharmacokinetic profiles in both seruni and ME. 
Chinchilla and gerbil models of ME infection are most 
commonly used. Dissimilarities of pharniacokinetic 
profiles between humans and animals limit extrapola- 
tion, especially with small animals which have a faster 
metabolism. However, precious supporting informa- 
tion has been obtained in pharmacokinetic studies 
of animals aimed at elucidating pathophysiologic 
problems or exploring the relationship between the 
treatment regimen, MEE concentration and bacterio- 
logic efficacy 
Pathophysiologic patterns have been studied in 
coinparisons of drug penetration in AOM and COME 
[8], and recent studies have focused on the influence of 
viral infections on drug penetration into MEE. Canafax 
et al. [31] developed a diffusion model in chinchillas 
and measured the elimination rate of locally admini- 
stered antibiotics. Using the same model Jossart et al. 
[32] compared drug elimination in animals infected 
with S. pneurnoniae alone, type A influenza virus alone, 
both pathogens and serous otitis media. They reported 
significantly faster drug elimination from effusions in 
animals infected by S. pneumoniae alone than in the 
other conditions. They assumed that the penetration 
rate was equal to the elimination rate, based on passive 
drug diffusion to the ear, and concluded that treatment 
failures in combined viral-pneurnococcal infection 
might be explained by reduced drug penetration. 
Mechanisms of drug activity can also be investi- 
gated in experimental studies. Girard et al. [33] studied 
the penetration of azithroniycin into gerbil MEE and 
found that the level of azithromycin correlated with the 
presence of inflammation, and that 70% of the drug was 
associated with cellular components in MEE. The 
synergism between a P-lactamase inhibitor (sulbactam) 
and ampicillin in AOM due to an ampicillin-resistant 
Haenzoplzilus in'7uenzae strain, was shown by Reilly et al. 
[34] in the chinchilla model. MlCs of both ampicillin 
and sulbactam were >50 pg/mL for the infecting 
strain. Despite a low maximal MEE concentration (5 
pg/mL) , sulbactam plus ampicillin significantly im- 
proved bacteriologic efficacy compared with ampicillin 
alone. 
A relationship between above-MIC MEE concen- 
trations and bacteriologic efficacy was evidenced in the 
chinchilla and gerbil models in pneumococcal and 
H. injluenzae infections [35-381. The relationship 
between dosing levels and MICs is of particular interest 
in the treatment of AOM due to penicillin-resistant 
strains. We studied the efficacy of increased doses of 
amoxicillin in the treatment of AOM due to penicillin- 
resistant strains of S. pneurnoniae in gerbils [36]. 
Increased doses of anioxicillin consistent with strain 
MICs were able to clear the ME infection. Pharmaco- 
kinetic data showed that ME concentrations were 
above the corresponding MICs for only part of the time 
between two injections but always for more than 
2.5 h. However, MEE concentrations above the MIC 
are not sufficient to predict the bacteriologic efficacy 
of time-dependent drugs. Rosenfeld et al. [39] 
obtained a failure rate of approximately 40%) with 
ceftibuten in pneuniococcal AOM in the chinchilla 
model, despite peak MEE levels above the MIC. We 
compared the efficacy of amoxicillin and ampicillin in 
the treatment of penicillin-resistant S. pneumoniae 
AOM in gerbils [40]. Despite similar kinetics in MEE 
after parenteral administration, ampicillin had lower 
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bacteriologic efficacy which could not be only explained 
by the MIC for the infecting strain. 
CONCLUSION 
Data on drug delivery to the middle ear provided 
by clinical studies are a usefd adjunct to in vitro and 
clinical trial data. However, they are not a very power- 
ful phaririacologic tool because of natural inter- 
individual variations arid ethical and methodological 
limitations. Experimental studies have made a niajor 
contribution to this field, as they permit investiga- 
tions of drug-host-pathogen links with bacteriologic 
efficacy and narrow the gap between data obtained in 
vitro and during clinical studies. 
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